Literature DB >> 6982472

Protection against syngeneic lymphoma by a long-lived cytotoxic T-cell clone.

M O Dailey, E Pillemer, I L Weissman.   

Abstract

The effect of a cloned T-cell line on the in vivo growth of syngeneic lymphoma cells was studied. 1E4 is an H-2-restricted cytotoxic T-cell clone that efficiently kills Abelson virus-induced lymphoma target cells (L1-2) at low effector/target ratios, as measured by in vitro cytotoxicity assays. In addition, it is long lived in vitro in the absence of stimulation and survives for more than 1 wk in vivo in the absence of exogenous antigen or growth factors. Mice injected intraperitoneally with lethal doses of L1-2 and then treated with 1E4 survived longer than animals treated with saline or with a control T-cell clone. Multiple weekly injections of effector cells, or a single injection in animals given a low dose of tumor cells, resulted in 50-80% long-term survivors. The observation that intravenous injection of killer cells was less effective than intraperitoneal treatment, coupled with the previous demonstration of markedly abnormal circulatory patterns for T-cell clones, suggests that those animals succumbing to progressively growing neoplasm die because the effector cells are unable to home into peripheral sites of tumor deposition. Thus, although this cytotoxic T-cell clone does have useful in vivo activity, its function may be partially limited by a generalized defect in migration.

Entities:  

Mesh:

Year:  1982        PMID: 6982472      PMCID: PMC346901          DOI: 10.1073/pnas.79.17.5384

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  20 in total

Review 1.  Passive immunotherapy of cancer in animals and man.

Authors:  S A Rosenberg; W D Terry
Journal:  Adv Cancer Res       Date:  1977       Impact factor: 6.242

2.  Inhibition of established transplants of chemically induced sarcomas in syngeneic mice by lymphocytes from immunized donors.

Authors:  H Borberg; H F Oettgen; K Choudry; E J Beattie
Journal:  Int J Cancer       Date:  1972-11       Impact factor: 7.396

3.  T cell growth factor: parameters of production and a quantitative microassay for activity.

Authors:  S Gillis; M M Ferm; W Ou; K A Smith
Journal:  J Immunol       Date:  1978-06       Impact factor: 5.422

4.  Abnormal migration of T lymphocyte clones.

Authors:  M O Dailey; C G Fathman; E C Butcher; E Pillemer; I Weissman
Journal:  J Immunol       Date:  1982-05       Impact factor: 5.422

5.  Specific adoptive therapy of established leukemia with syngeneic lymphocytes sequentially immunized in vivo and in vitro and nonspecifically expanded by culture with Interleukin 2.

Authors:  M A Cheever; P D Greenberg; A Fefer
Journal:  J Immunol       Date:  1981-04       Impact factor: 5.422

6.  Detection of early and delayed antitumor effects following curative adoptive chemoimmunotherapy of established leukemia.

Authors:  P D Greenberg; M A Cheever; A Fefer
Journal:  Cancer Res       Date:  1980-12       Impact factor: 12.701

7.  T cell-mediated immunosuppression as an obstacle to adoptive immunotherapy of the P815 mastocytoma and its metastases.

Authors:  E S Dye; R J North
Journal:  J Exp Med       Date:  1981-10-01       Impact factor: 14.307

8.  A critique of the evidence for active host defence against cancer, based on personal studies of 27 murine tumours of spontaneous origin.

Authors:  H B Hewitt; E R Blake; A S Walder
Journal:  Br J Cancer       Date:  1976-03       Impact factor: 7.640

9.  Quantitation and clonal isolation of cytolytic T lymphocyte precursors selectively infiltrating murine sarcoma virus-induced tumors.

Authors:  K T Brunner; H R MacDonald; J C Cerottini
Journal:  J Exp Med       Date:  1981-08-01       Impact factor: 14.307

10.  Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt-1+2- lymphocytes.

Authors:  P D Greenberg; M A Cheever; A Fefer
Journal:  J Exp Med       Date:  1981-09-01       Impact factor: 14.307

View more
  15 in total

1.  The augmentation of tumor-specific immunity using haptenic muramyl dipeptide (MDP) derivatives. III. Eradication of disseminated murine chronic leukemia cells by utilizing MDP hapten-reactive helper T-cell activity.

Authors:  J Shima; T Yoshioka; H Nakajima; H Fujiwara; T Hamaoka
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

2.  Defective generation of alloreactive cytotoxic T lymphocytes (CTL) in human monoclonal gammopathies.

Authors:  M Massaia; U Dianzani; A Bianchi; A Camponi; M Boccadoro; A Pileri
Journal:  Clin Exp Immunol       Date:  1988-08       Impact factor: 4.330

Review 3.  Immunology of metastasis. Can the immune response cope with disseminated tumor?

Authors:  P Frost; R S Kerbel
Journal:  Cancer Metastasis Rev       Date:  1983       Impact factor: 9.264

4.  CD4+ T-cell-dependent tumour rejection in an immune-privileged environment requires macrophages.

Authors:  Dru S Dace; Peter W Chen; Jerry Y Niederkorn
Journal:  Immunology       Date:  2007-10-17       Impact factor: 7.397

5.  Augmentation of the therapeutic efficacy of adoptive tumor immunotherapy by in vivo administration of slowly released recombinant interleukin 2.

Authors:  T Nishimura; Y Togashi; M Goto; H Yagi; Y Uchiyama; Y Hashimoto
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

6.  The use of cytotoxic T cells in the regulation of tumour growth in syngeneic mice.

Authors:  L Kwong; D G Kilburn; H S Teh
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

Review 7.  Helper strategy in tumor immunology: expansion of helper lymphocytes and utilization of helper lymphokines for experimental and clinical immunotherapy.

Authors:  G Forni; H Fujiwara; F Martino; T Hamaoka; C Jemma; P Caretto; M Giovarelli
Journal:  Cancer Metastasis Rev       Date:  1988-12       Impact factor: 9.264

8.  FBL-reactive CD8+ cytotoxic and CD4+ helper T lymphocytes recognize distinct Friend murine leukemia virus-encoded antigens.

Authors:  J P Klarnet; D E Kern; K Okuno; C Holt; F Lilly; P D Greenberg
Journal:  J Exp Med       Date:  1989-02-01       Impact factor: 14.307

9.  Human T cell clones express functional homing receptors required for normal lymphocyte trafficking.

Authors:  R F Navarro; S T Jalkanen; M Hsu; G Søenderstrup-Hansen; J Goronzy; C Weyand; C G Fathman; C Clayberger; A M Krensky; E C Butcher
Journal:  J Exp Med       Date:  1985-09-01       Impact factor: 14.307

10.  Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes.

Authors:  R J Barth; J J Mulé; P J Spiess; S A Rosenberg
Journal:  J Exp Med       Date:  1991-03-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.